Navigation Links
Stereotaxis Announces Second Quarter 2010 Earnings Release Date and Conference Call
Date:7/9/2010

ST. LOUIS, July 9 /PRNewswire-FirstCall/ -- Stereotaxis, Inc. (Nasdaq: STXS) announced today that it will release its financial results for the second quarter ended June 30, 2010, on Monday, August 2, 2010 after the close of the market. The Company will host a conference call and webcast on Monday, August 2, 2010 at 4:30 p.m. Eastern Time to discuss the Company's second quarter results and current corporate developments. Management is conducting the call earlier than its historical practice due to schedule conflicts.  The dial-in number for the conference call is 1-877-941-9205 for domestic participants and 1-480-629-9835 for international participants.

A taped replay of the conference call will also be available beginning approximately one hour after the call's conclusion and will be available for seven days.  This replay can be accessed by dialing 1-800-406-7325 for domestic callers and 303-590-3030 for international callers, both using passcode 4329312#.  The call will also be available on the Internet live and 90 days thereafter at the following URL:

http://www.videonewswire.com/event.asp?id=70601

About Stereotaxis

Stereotaxis designs, manufactures and markets an advanced cardiology instrument control system for use in a hospital's interventional s
'/>"/>

SOURCE Stereotaxis, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. New Data Demonstrate Safety, Efficacy of Stereotaxis for Patients with AFIB, VT and Congenital Defects
2. Stereotaxis and Siemens Promote Integrated Odyssey(TM) Solutions
3. Stereotaxis Announces Vdrive(TM), a New Technology for Remote Navigation of Diagnostic Devices
4. Stereotaxis Updates Progress on Major Clinical Initiative Related to Electrophysiology (EP) Treatment of Ventricular Tachycardia
5. Stereotaxis Installs First System in Taiwan
6. Stereotaxis System Procedure Featured on NBCs The TODAY Show
7. Stereotaxis is Notified of the FDA Approval of an Additional Magnetic Irrigated Catheter
8. Stereotaxis Receives Notice of European Approval of an Additional Magnetic Irrigated Catheter
9. Stereotaxis Announces Underwriters Exercise of Over-Allotment Option
10. Stereotaxis Announces Pricing of $26 Million Common Stock Offering
11. Stereotaxis Announces Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... , May 21, 2013  Cephasonics, a ... today announced the introduction of the cQuest ... network-based communications with all cQuest Ultrasound™ hardware ... technology, including this new capability, at Hospitalar ... Brazil from May 21-24.  Cephasonics ...
(Date:5/21/2013)... May 21, 2013 BioElectronics Corp. (PINKSHEETS: ... electronic devices, announced that CEO, Andrew ... the FDA,s Medical Advisory Committee, Orthopedic and Rehabilitation ... for over the counter sales. "It,s ... medical device classification schema," Whelan said.  "While the ...
(Date:5/21/2013)...  Janssen R&D Ireland (Janssen) today announced primary ... 3 PROMISE study demonstrating that use of the ... virologic response 12 weeks after the end of ... 1 chronic hepatitis C adult patients with compensated ... when administered once daily with pegylated interferon and ...
Breaking Medicine Technology:Cephasonics Unveils Next-Generation Wireless-Imaging Technology for cQuest Ultrasound Hardware Platforms 2BioElectronics Presents FDA Reclassification Panel 2BioElectronics Presents FDA Reclassification Panel 3Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 2Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 3Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 4Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 5Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 6Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 7
... 7 NeuroVasx, Inc. announced,today the completion of a private ... of Minneapolis, MN and the Stephens Group of Little,Rock, AR. ... also announced completion of long term follow up on 20,patients ... which was completed in May. The company intends to announce ...
... Genomic Health,Inc. (Nasdaq: GHDX ) today announced ... DX(R) breast cancer test are scheduled to be ... Symposium, taking place,December 13-16, 2007. Oncotype DX is ... the likelihood of recurrence and the likelihood,of chemotherapy ...
Cached Medicine Technology:Genomic Health Announces Eight Oncotype DX(R) Studies to Be Presented at 30th Annual San Antonio Breast Cancer Symposium 2Genomic Health Announces Eight Oncotype DX(R) Studies to Be Presented at 30th Annual San Antonio Breast Cancer Symposium 3
(Date:5/21/2013)... 21, 2013 According to a May 13, ... Use of Botox,” Botox injections have become the ... in 2002 (Go to goo.gl/8iYbD). Although it is mostly associated ... men. The injection makes facial wrinkles less visible by paralyzing ... for about three months. This means that people who are ...
(Date:5/21/2013)... Diversity Focus, a non-profit organization striving to ... in the Creative Corridor region, is releasing results for ... conference on Thursday, May 23rd at 10:30 a.m. ... , The survey is a critical component ... that attract, nurture and retain people of diverse backgrounds, ...
(Date:5/21/2013)... (May 21, 2013) A paper recently published in ... co-written by physicians and scientists at the University of ... risk factor for pulmonary fibrosis can be used to ... , Researchers looked at a fairly common variant of ... component of the mucous produced by the bronchial tubes. ...
(Date:5/21/2013)... for scientific and technological research So Paulo Research Foundation, ... an investment estimated in US$ 680 million to support ... period of up to eleven years, subject to continuation ... Funding for the 17 RIDCs will come from FAPESP ... personnel, and infrastructure). Host institutions will participate in a ...
(Date:5/21/2013)... Park City, Utah (PRWEB) May 21, 2013 ... on HRA, HSA and FSA accounts. Zane ... employer sponsored health benefits, is the leader in ... health reimbursement arrangements . , According to Zane ... or health reform) was signed into law in 2010 ...
Breaking Medicine News(10 mins):Health News:Botox – Is the World’s Most Popular Cosmetic Procedure Safe? 2Health News:Diversity Focus Announces Results from 2013 Creative Corridor Survey at News Conference on Thursday, May 23rd at 10:30 a.m. 2Health News:Researchers find genetic risk factor for pulmonary fibrosis 2Health News:Research at the cutting edge of knowledge 2Health News:Zane Benefits Publishes New Information on HRA, HSA and FSA Accounts 2Health News:Zane Benefits Publishes New Information on HRA, HSA and FSA Accounts 3
... rates of hospital use, but they may be experiencing ... said in the latest edition of the Medical ... Melbourne-based Refugee Health Research Centre, Dr Ignacio Correa-Velez, and ... financial years to June 2004. ,'We found ...
... -- The science has long been clear that smoking causes ... damage from a father who smokes . ,Canadian ... in the DNA sequence of sperm cells, alterations that could ... are published in the June 1 issue of Cancer Research, ...
... market is estimated at around $2.5 trillion per annum, ... percent per annum. A radical shift in food consumption ... ,In markets, especially in the developed world, with ... is rapidly increasing. Besides, the emerging health-conscious newer generation ...
... released by a growing tumor could one day become ... chemotherapy and radiation treatment in people with advanced throat ... 1, 2007, issue of Clinical Cancer Research. ... Communication Disorders (NIDCD) and National Cancer Institute (NCI), two ...
... Researchers have found that patients with obstructive sleep apnea ... dead cells (apoptotic cells) from the lining (endothelium) of ... who do not have OSA. The finding may help ... for cardiovascular disease (CVD). ,According to the ...
... In a retrospective study of 700 patients with ... be significantly higher in HIV-infected patients compared ... TB relapse rates were higher in HIV-infected patients ... compared to those receiving daily or longer treatment. ...
Cached Medicine News:Health News:Cigarette Smoke Alters DNA in Sperm, Genetic Damage Could Pass to Offspring 2Health News:Nutrient-rich Dairy Beverages an Emerging Market 2Health News:Blood Test may Help Signal Tumor's Remission, Return in Throat Cancer Patients 2Health News:Blood Test may Help Signal Tumor's Remission, Return in Throat Cancer Patients 3Health News:Blood Test may Help Signal Tumor's Remission, Return in Throat Cancer Patients 4Health News:Patients With OSA at Higher Risk for Cardiovascular Disease 2Health News:Patients With OSA at Higher Risk for Cardiovascular Disease 3Health News:Treatment Outcomes of Patients With HIV and Tuberculosis 2
Inquire...
Remote Blower With Bag-In/Bag-Out Option...
Class II Type B2 Biological Safety Cabinet...
Class II Type A2 Biological Safety Cabinet...
Medicine Products: